<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798304</url>
  </required_header>
  <id_info>
    <org_study_id>6108K2-2000</org_study_id>
    <secondary_id>B1971008</secondary_id>
    <secondary_id>2008-001457-18</secondary_id>
    <nct_id>NCT00798304</nct_id>
  </id_info>
  <brief_title>Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants</brief_title>
  <official_title>An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and immunogenicity of an
      investigational meningococcal B vaccine in healthy infants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following program review within Pfizer, decision was made not to go ahead with this study. This
    study is cancelled
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving at Least 1:4 rLP2086-specific Serum Bactericidal Assay (SBA) Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</measure>
    <time_frame>1 month after Dose 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>From signing of informed consent form to completion of study (up to 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Assay (SBA) Geometric Mean Titers (GMTs) for 1 Subfamily A Strain and 1 Subfamily B Strain</measure>
    <time_frame>1 month after Dose 2, Dose 3; before Dose 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 rLP2086-specific SBA Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</measure>
    <time_frame>1 month after Dose 2, Dose 3; before Dose 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving Response &gt;=1:4 for Additional Meningococcal Serogroup B (MnB) Test Strain-specific SBA Titer</measure>
    <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving SBA Titer Levels &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Additional MnB Test Strains</measure>
    <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum Bactericidal Assay (SBA) GMTs for Additional MnB Test Strains</measure>
    <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>meningococcal B rLP2086 vaccine</intervention_name>
    <description>vaccination</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Routine age appropriate childhood vaccines</intervention_name>
    <description>vaccination</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>meningococcal B rLP2086 vaccine</intervention_name>
    <description>vaccination</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Routine age appropriate childhood vaccines</intervention_name>
    <description>vaccination</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Routine age appropriate childhood vaccines</intervention_name>
    <description>vaccination</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Investigators should always use good clinical judgment in considering a subject's
             overall fitness for trial participation. In addition, any condition that in the
             opinion of the investigator may interfere with the evaluation of study objectives
             should be carefully considered prior to enrolling subjects.

          -  Male or female subjects aged 2 months (42 to 98 days of age) at the time of
             enrollment.

          -  Available for the entire consented period and whose parent/legal guardian can be
             reached by telephone.

          -  Healthy infant as determined by medical history, physical examination, and judgment of
             the investigator.

          -  Parent/legal guardian must be able to complete all relevant study procedures during
             study participation.

        Exclusion Criteria:

          -  Previous vaccination with licensed or investigational vaccines: meningococcal B,
             meningococcal C, pneumococcal, Hib, diphtheria, tetanus, acellular pertussis,
             poliovirus, rotavirus, varicella, measles, mumps, or rubella.

        Any of the following illnesses/conditions that, in the investigator's judgment, will
        substantially increase the risk associated with the subject's participation in and
        completion of the study:

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Contraindication to vaccination with meningococcal B, meningococcal C, pneumococcal,
             Hib, diphtheria, tetanus, acellular pertussis, Hepatitis B (HBV), poliovirus,
             rotavirus, varicella, measles, mumps, or rubella.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  Known or suspected immune deficiency or suppression.

          -  History of culture-proven invasive disease caused by N meningitidis or Neisseria
             gonorrhoea.

          -  Major known congenital malformation or serious chronic disorder.

          -  Significant neurological disorder or history of seizure including febrile seizure, or
             significant stable or evolving disorder such as cerebral palsy, encephalopathy,
             hydrocephalus, or other significant disorder.

        Does not include resolving syndromes due to birth trauma such as Erb palsy.

          -  Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and
             monoclonal antibodies).

          -  Received any investigational drugs, vaccines or devices (aside from those specified in
             the protocol) within 4 weeks before administration of the first dose of test article
             or at any time throughout the study.

          -  Participation in purely observational studies is acceptable.

          -  Infant who is a direct descendant (child, grandchild) of the study site personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiado de Compostela</city>
        <state>La Coru√±a</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Most√≥les</name>
      <address>
        <city>Most√≥les</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Camino</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica Mediterr√°neo</name>
      <address>
        <city>Almeria</city>
        <zip>4007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral. Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre Materno-Infantil Unidad de Lactantes</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <zip>36024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6108K2-2000&amp;StudyName=Study%20Evaluating%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20Meningococcal%20B%20Vaccine%20in%20Healthy%20Infants</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>November 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>November 21, 2014</last_update_submitted>
  <last_update_submitted_qc>November 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal B vaccine</keyword>
  <keyword>infants</keyword>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this study, participants were to receive recombinant lipoprotein 2086 (rLP2086) vaccine at 2, 4, 6 and 12 months of age. Due to premature termination of study, only single dose of 20 or 60 microgram (mcg) of rLP2086 vaccine was administered at 2 months and planned treatments of rLP2086 vaccine 120 mcg and 200 mcg were not administered.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
        </group>
        <group group_id="P2">
          <title>rLP2086 20 mcg</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
        <group group_id="P3">
          <title>rLP2086 60 mcg</title>
          <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
        </group>
        <group group_id="B2">
          <title>rLP2086 20 mcg</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
        <group group_id="B3">
          <title>rLP2086 60 mcg</title>
          <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="11.57"/>
                    <measurement group_id="B2" value="64.0" spread="10.02"/>
                    <measurement group_id="B3" value="71.6" spread="11.35"/>
                    <measurement group_id="B4" value="65.5" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving at Least 1:4 rLP2086-specific Serum Bactericidal Assay (SBA) Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</title>
        <time_frame>1 month after Dose 3</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least 1:4 rLP2086-specific Serum Bactericidal Assay (SBA) Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Assay (SBA) Geometric Mean Titers (GMTs) for 1 Subfamily A Strain and 1 Subfamily B Strain</title>
        <time_frame>1 month after Dose 2, Dose 3; before Dose 4</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay (SBA) Geometric Mean Titers (GMTs) for 1 Subfamily A Strain and 1 Subfamily B Strain</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 rLP2086-specific SBA Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</title>
        <time_frame>1 month after Dose 2, Dose 3; before Dose 4</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least 1:4, 1:8, 1:16, 1:32, 1:64, 1:128 rLP2086-specific SBA Titer to 1 Subfamily A Strain and 1 Subfamily B Strain</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Response &gt;=1:4 for Additional Meningococcal Serogroup B (MnB) Test Strain-specific SBA Titer</title>
        <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Response &gt;=1:4 for Additional Meningococcal Serogroup B (MnB) Test Strain-specific SBA Titer</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving SBA Titer Levels &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Additional MnB Test Strains</title>
        <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SBA Titer Levels &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64 and &gt;=1:128 for Additional MnB Test Strains</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serum Bactericidal Assay (SBA) GMTs for Additional MnB Test Strains</title>
        <time_frame>1 month after Dose 2, Dose 3; before Dose 4; 1, 6, 12, 18, 24, 36, 48 months after Dose 4</time_frame>
        <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay (SBA) GMTs for Additional MnB Test Strains</title>
          <population>Results were not reported for this outcome measure because the study was terminated prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
        <time_frame>From signing of informed consent form to completion of study (up to 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>rLP2086 20 mcg</title>
            <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
          <group group_id="O3">
            <title>rLP2086 60 mcg</title>
            <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="31.8"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs/SAEs: recorded from signing of informed consent form to completion of study (up to 2 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Routine childhood vaccines (InfanrixHexa, Meningitec, Prevenar and Rotarix) according to local practice.</description>
        </group>
        <group group_id="E2">
          <title>rLP2086 20 mcg</title>
          <description>Recombinant lipoprotein 2086 (rLP2086) 20 microgram (mcg) vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
        <group group_id="E3">
          <title>rLP2086 60 mcg</title>
          <description>rLP2086 60 mcg vaccine along with routine childhood vaccines according to local practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Immunogenicity results were not reported because the study was terminated due to the reactogenicity profile of the vaccine in infants prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

